Investigation of established genetic risk variants for glioma in prediagnostic samples from a population-based nested case-control study

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 5, 2015, Pages 810-816

  Wibom, Carl ^a   Späth, Florentin ^a   Dahlin, Anna M ^a   Langseth, Hilde ^b   Hovig, Eivind ^c,d   Rajaraman, Preetha ^e   Johannesen, Tom Børge ^b   Andersson, Ulrika ^a   Melin, Beatrice ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; ANRIL LONG NON-CODING RNA, HUMAN; CCDC26 PROTEIN, HUMAN; DNA HELICASE; LONG UNTRANSLATED RNA; NERVE PROTEIN; PHLDB1 PROTEIN, HUMAN; RTEL1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CCDC26 GENE; CDKN2B AS1 GENE; CONTROLLED STUDY; FEMALE; GENE; GENETIC RISK; GENETIC VARIABILITY; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PHLDB1 GENE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RTEL1 GENE; BRAIN TUMOR; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; MORTALITY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PROTO ONCOGENE; REGISTER; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; DNA HELICASES; FEMALE; GENES, ERBB-1; GENETIC VARIATION; GLIOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; RNA, LONG NONCODING; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84938591734     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1106     Document Type: Article

References (32)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapywith concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
2. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012;14:v1-v49.
3. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93-108.
4. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 2000;5: D213-D31.
5. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il'Yasova D, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008;113:1953-68.
6. Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I. Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res 2005;163: 424-32.
7. Braganza MZ, Kitahara CM, Berringtonde Gonzalez A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol 2012;14:1316-24.
8. Malmer B, Henriksson R, Gronberg H. Familial brain tumours-Genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. Int J Cancer 2003; 106:260-3.
9. Scheurer ME, Etzel CJ, Liu M, El-Zein R, Airewele GE, Malmer B, et al. Aggregation of cancer in first-degree relatives of patients with glioma. Cancer Epidemiol Biomarkers Prev 2007;16:2491-5.
10. Wrensch M, Lee M, Miike R, Newman B, Barger G, Davis R, et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol 1997;145:581-93.
11. Rajaraman P, Melin BS, Wang Z, McKean-Cowdin R, Michaud DS, Wang SS, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet 2012;131:1877-88.
12. Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 2009;41:905-8.
13. Sanson M, Hosking FJ, Shete S, Zelenika D, Dobbins SE, Ma Y, et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet 2011;20:2897-904.
14. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009;41:899-904.
15. Simon M, Hosking FJ, Marie Y, Gousias K, Boisselier B, Carpentier C, et al. Genetic risk profiles identify different molecular etiologies for glioma. Clin Cancer Res 2010;16:5252-9.
16. Jenkins RB, Wrensch MR, Johnson D, Fridley BL, Decker PA, Xiao Y, et al. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet 2011;204:13-8.
17. Enciso-Mora V, Hosking FJ, Kinnersley B, Wang Y, Shete S, Zelenika D, et al. Deciphering the 8q24.21 association for glioma. Hum Mol Genet 2013;22:2293-302.
18. Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 2011;43:1098-103.
19. Andersson U, Schwartzbaum J, Wiklund F, Sjostrom S, Liu Y, Tsavachidis S, et al. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol 2010;49:767-75.
20. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010;42:224-8.
21. Jellum E, Andersen A, Lund-Larsen P, Theodorsen L, Orjasaeter H. The JANUS serum bank. Sci Total Environ 1993;139-140:527-35.
22. Jellum E, Andersen A, Lund-Larsen P, Theodorsen L, Orjasaeter H. Experiences of the Janus Serum Bank in Norway. Environ Health Perspect 1995;103 Suppl 3:85-8.
23. Bjorheim J, Gaudernack G, Giercksky KE, Ekstrom PO. Direct identification of all oncogenic mutants in KRAS exon 1 by cycling temperature capillary electrophoresis. Electrophoresis 2003;24:63-9.
24. Ekstrom PO, Bjorge T, Dorum A, Longva AS, Heintz KM, Warren DJ, et al. Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis. Anal Chem 2004;76:4406-9.
25. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155: 462-77.
26. Chakravarti A, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A, et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001;7:2387-95.
27. Sjöström S, Andersson U, Liu Y, Brännström T, Broholm H, Johansen C, et al. Genetic variations in EGF and EGFR and glioblastoma outcome. Neuro Oncol 2010;12:815-21.
28. Melin BS, Nordfjall K, Andersson U, Roos G. hTERT cancer risk genotypes are associated with telomere length. Genet Epidemiol 2012;36:368-72.
29. Walcott F, Rajaraman P, Gadalla SM, Inskip PD, Purdue MP, Albanes D, et al. Telomere length and risk of glioma. Cancer Epidemiol 2013;37: 935-8.
30. Wang S, Chen Y, Qu F, He S, Huang X, Jiang H, et al. Association between leukocyte telomere length and glioma risk: a case-control study. Neuro Oncol 2014;16:505-12.
31. Enciso-Mora V, Hosking FJ, Di Stefano AL, Zelenika D, Shete S, Broderick P, et al. Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222. Br J Cancer 2013;108:2178-85.
32. Bjorge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 2004;91:1829-34.